We are searching for the causes
and developing safe, new treatments for patients with lupus and other autoimmune diseases
Finding Inspiration in Every Turn
-
Our clinical trials have provided preliminary evidence that blockade of the mechanistic target of rapamycin improves disease outcomes in patients with systemic lupus erythematosus
​
Beyond taming lupus, N-acetylcysteine or NAC improves fatigue and sirolimus extends life span across many studies...
Meet The Team
Andras Perl, MD, PhD
Founder & PI
Bryan Blaker, MS
Study Coordinator
Ioana Comam, PhD
Project and Data Manager
Akshay Patel, MS
MD/PhD Student
Aparna Godavarthy, PhD
Postdoctoral Fellow
Jessica Nolan, MS
Senior Research Specialist
Joshua Lewis, BS
Laboratory Manager
Joy Park, BS
PhD Student
Thomas Winans, PhD
Postdoctoral Fellow
Xiaojing Wang, MD
Senior Research Specialist
Joanne Chilton, CCRP
Project Manager
Dilip Rao, MS
Senior Research Specialist
The Story of Torapeutics
Our search for safe and effective treatments for meeting a significant unmet need in patients with lupus has focused the the metabolic causes of this disease for over two decades. Our dedicated team has discovered genetic and environmental causes that effect disease development through metabolism.
Our discoveries of mitochondrial dysfunction and depletion of intracellular glutathione, which is the primary antioxidant in human cells, led to the introduction of NAC for treatment of SLE.
Our discovery of the activation of the mechanistic target of rapamycin, as a sensor of mitochondrial dysfunction and inflammatory lineage development in the immune system prompted us to evaluate the efficacy of rapamycin, also known as sirolimus., in patients with SLE.
Our Clients
